Advertisement
Advertisement

ELVN

ELVN logo

Enliven Therapeutics, Inc. Common Stock

29.45
USD
Sponsored
+2.46
+9.11%
Feb 06, 15:59 UTC -5
Closed
exchange

After-Market

29.31

-0.14
-0.48%

ELVN Earnings Reports

Positive Surprise Ratio

ELVN beat 16 of 22 last estimates.

73%

Next Report

Date of Next Report
Mar 11, 2026
Estimate for Q4 25 (Revenue/ EPS)
$8.50K
/
-$0.38
Implied change from Q3 25 (Revenue/ EPS)
--
/
+18.75%
Implied change from Q4 24 (Revenue/ EPS)
--
/
-17.39%

Enliven Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 12, 2025, ELVN reported earnings of -0.32 USD per share (EPS) for Q3 25, beating the estimate of -0.44 USD, resulting in a 27.67% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -0.15% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 12 analysts forecast an EPS of -0.38 USD, with revenue projected to reach 8.50 thousand USD, implying an increase of 18.75% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
For Q3 2025, Enliven Therapeutics, Inc. Common Stock reported EPS of -$0.32, beating estimates by 27.67%, and revenue of $0.00, 0% as expectations.
The stock price moved down -0.15%, changed from $20.30 before the earnings release to $20.27 the day after.
The next earning report is scheduled for Mar 11, 2026.
Based on 12 analysts, Enliven Therapeutics, Inc. Common Stock is expected to report EPS of -$0.38 and revenue of $8.50K for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement